Chemical subgroup
A10BK – Natrium-Glucose-Cotransporter-2-(SGLT2)-Inhibitoren
12Decisions
41Patient groups
Added benefit by patient group
- Considerable6
- Minor8
- Not proven27
Decisions, newest first
- 2024-06-20JardianceEmpagliflozinNot proven
- 2024-02-01JardianceEmpagliflozinNot proven
- 2023-08-17ForxigaDapagliflozinMinor
- 2022-09-15JardianceEmpagliflozinMinor
- 2022-06-16ForxigaDapagliflozinNot proven: 2 of 2 patient groups
- 2022-05-19SteglatroErtugliflozinNot proven: 8 of 8 patient groups
- 2022-02-17ForxigaDapagliflozinConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2022-01-06JardianceEmpagliflozinMinor
- 2021-05-20ForxigaDapagliflozinConsiderable
- 2019-12-19ForxigaDapagliflozinMinor: 3 of 8 patient groupsNot proven: 5 of 8 patient groups
- 2016-09-01JardianceEmpagliflozinConsiderable: 4 of 10 patient groupsMinor: 1 of 10 patient groupsNot proven: 5 of 10 patient groups
- 2014-09-04InvokanaCanagliflozinNot proven: 5 of 5 patient groups
Data status: 2026-10-29